ArticleMolecular medicine reports2017
AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Integrated Proteomic and Metabolomic Analyses Characterise Molecular Alterations Associated with JSRV-Induced OPA.Biology · 2026Article
- AKAP2 is required for assembly of cytoskeletal signaling complexes that promote growth and metastasis of triple-negative breast cancer.The Journal of biological chemistry · 2026Article
- Subcellular Stress Markers in Epithelial Ovarian Cancer.International journal of molecular sciences · 2025Review
- Protein kinase A and local signaling in cancer.The Biochemical journal · 2024Review
- Proteomic analysis reveals a PLK1-dependent G2/M degradation program and a role for AKAP2 in coordinating the mitotic cytoskeleton.Cell reports · 2024Article
- Breast adipose tissue-derived extracellular vesicles from obese women alter tumor cell metabolism.EMBO reports · 2023Article
- Integrative analysis identifies AKAP8L as an immunological and prognostic biomarker of pan-cancer.Aging · 2023Article
- Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis.Frontiers in endocrinology · 2023Article
- Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.Journal of translational medicine · 2022Article
- Subcellular Organization of the cAMP Signaling Pathway.Pharmacological reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations of A‑kinase anchoring protein 2 (AKAP2) have been reported to be associated with adolescent idiopathic scoliosis. However, its role in cancer is poorly understood. In the present study, the mRNA levels of AKAP2 in ovarian cancer tissues were examined using qPCR. The effects of AKAP2 on the growth and migration of cancer cells were examined using crystal violet and Boyden chamber assays. An in vivo image system was used to evaluate the effect of AKAP2 on the metastasis of ovarian cancer cells. The present study demonstrated that the expression of AKAP2 was elevated in ovarian cancer. Furthermore, overexpression of AKAP2 promoted the growth and migration of ovarian cancer cells, whereas knockdown of AKAP2 expression reduced the growth and migration of ovarian cancer cells. Analysis of the molecular mechanism indicated that AKAP2 activated β‑catenin/T cell factor signaling and regulated the expression of several target genes. Furthermore, analysis of the in vivo metastatic capacity demonstrated that downregulation of AKAP2 inhibited the invasion of ovarian cancer cells. Taken together, the present study demonstrated an oncogenic role for AKAP2 in ovarian cancer, indicating that AKAP2 may be a therapeutic target for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.